Our new article “Sex-related cardiometabolic differences in ME/CFS patients” is now out!

The WE&ME Foundation (@weandmecfs) and WWTF are launching the ME/CFS Fellowships 2026 — funding 6-month research stays with up to €40,000 per fellowship (total €200,000). A great opportunity to connect people and to advance ME/CFS science. (Link with specifics in the comments.)

https://t.co/snugNCJ1K9

Interested in the details? Read the full article here: https://t.co/KLVvV17BWO

These findings suggest that sex- and posture-related cardiometabolic differences may support better patient stratification in ME/CFS.

Key findings: • In ME/CFS patients, cardiovascular differences are more pronounced during standing than sitting, in both sexes. • Male patients showed higher levels of AOPP, a marker of oxidative stress, compared to females.

🎯To quantify the cardiorenal benefits of combination regimens with GLP-1RA, SGLT2i, and/or finerenone versus corresponding monotherapies. 👥Systematic review and meta-analysis of post hoc analyses of RCTs and 10 observational studies that met prespecified inclusion criteria.

📌Sub-analysis of the EmDia trial (NCT02932436) 🎯To assess changes in lipid profiles driven by Empagliflozin use in HF patients. 👥 Lipid analysis of blood plasma from 144 pts was conducted using 4D-LC-TIMS/IMS lipidomics and repeated after one and twelve weeks of treatment.

📌DAPAHEART trial: a single-center, 4-week, randomized (1:1 dapagliflozin 10 mg vs. placebo), double-blind, controlled study. 🎯To assess the long-term impact of dapagliflozin on CFR and EAT thickness in T2DM patients with CAD. 👥N=16 pts w/ T2DM+CAD were enrolled in the

🎯 Meta-analysis to provide the NNT and efficacy of GLP-1RA in reducing risk of myocardial infarction (MI). 👥109,846 pts from 25 studies. Risk-reduction effect of GLP-1RA were pooled using pairwise meta-analysis with a random-effects model. The primary outcome was MI, and

🔥Proud to share that #CardiovascularDiabetology has achieved a new Impact Factor of 10.6 - its highest since 2009 - reinforcing its position among the leading journals in the Cardiovascular and Endocrinology & Metabolism fields. 🎯The journal now ranks 14th out of 230 in the

🎯To evaluate the impact of #SGLT2i on the risk of acute kidney injury (AKI) in #T2DM pts w/ severe #AS undergoing #TAVI. 👥 Multicenter Registry of consecutive pts stratified by the presence of CKD and anti-diabetic therapy (2021-2024). 🔥Our main findings were: - SGLT2i

🚨We're thrilled to launch Cardiovascular Diabetology’s #KnowTheAuthors project - giving visibility to the brilliant minds behind the science! 🎥 First up: Maria Barranco-Altirriba presents key insights from her study on lipidomics and subclinical carotid atherosclerosis in T2D

👉Pts with both AS and DM face challenges arising from the interaction between the 2 conditions. 🎯To investigate the effects of DM on the LV remodelling in AS patients, specifically focusing on the inflammatory response and oxidative stress. 👥 LV myocardial biopsies were

🎯To assess cardiovascular, metabolic, and renal effects of combination therapy w/ GLP-1RA+SGLT2i compared to SGLT2i alone. 👥Komodo’s Healthcare Map (2017- 2023) including 100,455 people in the combination GLP-1RA+SGLT2i group and 339,540 people in the SGLT2i alone group,

🎯To evaluate the cardiorenal protective effects of dapagliflozin in T2DM pts w/ CCS undergoing PCI. 👥Cross-sectional analysis of 1:1 PSM pts: 176 dapagliflozin vs. 176 control from a tertiary hospital undergoing PCI (January 2018 - March 2022). 📊 After adjusting for

🩸Diabetes is on the rise...This review explores how exercise & diet can be powerful tools against diabetic cardiomyopathy (DCM), offering hope beyond meds💊. https://t.co/K4rWLBsuQz 👨‍🍳Diet shows both beneficial and adverse impacts on cardiac metabolism. 🏃‍♀️Exercise regimens

🎯To explore the incremental predictive value of liver fat fraction (LFF) on MACE occurrence in T2DM pts. 👥265 T2DM pts w/ suspected CAD undergoing CCTA+upper abdominal dual-layer spectral detector computed tomography (SDCT) examinations within a 7-day interval. 📊 Elevated

🎯 To evaluate whether baseline PCATa predicts changes in plaque composition/burden over 12 months in DM pts. 👥Prospective longitudinal study including 200 T2DM pts, without symptoms or known CAD (mean age 61 ± 9.4 yrs, 72% male). 📌High PCATa levels were determined using the

👥84,656 individuals from the UK Biobank w/ validated accelerometry data and no T2DM were included. 🤸‍♂️Data on physical activity (PA) was collected using the Axivity AX3 wrist-based triaxial accelerometer worn for 1week. Participants were categorized into 3 PA patterns: -